Skip to content
Open access

Impact of extranodal disease burden on survival following CAR-T therapy in relapsed/refractory large B-cell lymphoma: A propensity score-matched multi-center analysis.

Oct 2026 · JCO Oncology Practice · Vol 22, pp. 640-640 · 0 citations

TL;DR

Overall survival, CRS, ICANS, and sepsis rates were comparable between extranodal and nodal disease cohorts, and CAR-T therapy as equally effective in extranodal involvement should not influence treatment eligibility decisions.

Abstract

640 Background: Extranodal involvement in large B-cell lymphoma (LBCL) has traditionally been associated with more aggressive disease and poorer outcomes with conventional therapies. Whether this adverse prognostic effect persists in the era of chimeric antigen receptor T-cell (CAR-T) therapy remains unclear. We evaluated the impact of extranodal disease on survival and treatment-related toxicities following CAR-T therapy in a large real-world cohort. Methods: Using the TriNetX Global Collaborative Network, we identified adult patients with relapsed/refractory LBCL who underwent CAR-T therapy. Patients were categorized into extranodal LBCL and nodal LBCL cohorts. Propensity score matching (1:1) was performed to balance demographics, comorbidities, and disease-related characteristics. The primary outcome was all-cause mortality. Secondary outcomes included cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and sepsis. Kaplan–Meier analyses, hazard ratios, and risk estimates were calculated. Results: After matching, 681 patients were included in each cohort. All-cause mortality occurred in 34.0% of the extranodal group versus 38.6% of the nodal group (RR 0.88, 95% CI 0.76–1.01; p=0.075). Median overall survival was 1,572 days in the extranodal cohort compared with 1,438 days in the nodal cohort, but Kaplan–Meier analysis showed no statistically significant difference (HR 0.92, 95% CI 0.77–1.09; log-rank p=0.334). CRS occurred in 50.1% vs 50.7% (RR 0.99, p=0.839), with no difference in CRS-free survival (HR 0.95, p=0.512). ICANS occurred in 22.8% vs 26.8% (RR 0.85, p=0.115), with no significant difference in ICANS-free survival (HR 0.84, p=0.137). Sepsis rates were similar (22.6% vs 23.4%; RR 0.97, p=0.771), with comparable sepsis-free survival (HR 1.01, p=0.929). Conclusions: In this large, propensity score-matched real-world study, extranodal disease did not adversely impact outcomes following CAR-T therapy in patients with R/R LBCL. Overall survival, CRS, ICANS, and sepsis rates were comparable between extranodal and nodal disease cohorts. Although a numerical trend toward improved survival was observed among patients with extranodal involvement, the difference was not statistically significant. These findings suggest that CAR-T therapy as equally effective in extranodal involvement should not influence treatment eligibility decisions.

Read PDF

Similar papers

Oct 2026

CAR T-cell therapy for relapsed and refractory B-cell non-Hodgkin lymphoma: a single-centre 5-year real-world experience study at Ghent University Hospital.

BACKGROUND Relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) remains challenging to treat, particularly in patients ineligible for high-dose chemotherapy and autologous stem cell transplantation. Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment. AIMS We describe the e...

Julie Vandewiele, Chiel Gharakhani, C. De Vriendt et al. · 0 citations
Nov 2026

Multiple and central nervous system extranodal involvement predict poor prognosis in R/R DLBCL following CD19 CAR-T therapy.

BACKGROUND CD19 chimeric antigen receptor T-cell (CAR-T) therapy has achieved remarkable results in treating patients with refractory or relapsed diffuse large B-cell lymphoma (R/R DLBCL). Nevertheless, certain limitations still persist. This study focuses on the impact of extranodal involvement before treatment on the...

Ji-Le Liu, Mo-Han Zhao, Xiu Liu et al. · 0 citations
Open access Oct 2026

Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma.

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment for patients with aggressive relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). One notable complication is immune effector cell-associated neurotoxicity syndrome (ICANS) which can be life-threatening. Treatment includes supportive...

Vivek G. Patel, Shakthi T. Bhaskar, S. Schuster et al. · 0 citations
Oct 2026

Impact of chronic obstructive pulmonary disease on survival after chimeric antigen receptor T-cell therapy in large B-cell lymphoma.

BACKGROUND Chimeric antigen receptor T-cell (CAR T-cell) therapy is the standard of care for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). The impact of pre-existing chronic obstructive pulmonary disease (COPD) on outcomes of LBCL after CAR-T cell therapy are not well characterized. This study aimed at evalua...

M. Uyanik, Athanasios Tsalatsanis, I. Muhsen et al. · 0 citations
Open access Oct 2026

Comparative effectiveness of CAR-T cell therapy and CD20xCD3 bispecific antibodies in relapsed/refractory follicular lymphoma: A propensity score–matched real-world analysis.

639 Background: CD20×CD3 bispecific antibodies and chimeric antigen receptor T-cell (CAR-T) therapy have expanded treatment options for relapsed/refractory follicular lymphoma (R/R FL). Although both therapies demonstrate substantial clinical activity, comparative real-world data remain limited. We compared sur...

Navya Pillikunte Doddareddy, Ranjit Sah, G. Sorescu · 0 citations
Open access Nov 2026

Relapse patterns and clinical outcomes after BCMA-directed CAR-T therapy in multiple myeloma: a real-world single-center study

Despite deep remissions achieved with B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory multiple myeloma (MM), most patients eventually relapse. Although extramedullary disease (EMD) has been associated with poor prognosis after BCMA-directed CAR-T the...

Qi-Ling Bu, Yi-Wen Jiang, Hui-Xing Zhou et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.